Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...
-
Los Angeles, California, March 31, 2022 (GLOBE NEWSWIRE) -- Crown Electrokinetics Corp. (NASDAQ: CRKN) ("Crown" or the "Company"), a leading smart glass technology company, reported today its...
-
VANCOUVER, British Columbia, March 31, 2022 (GLOBE NEWSWIRE) -- Norsemont Mining Inc. (CSE: NOM, OTCQB: NRRSF, FWB: LXZ1) (“Norsemont” or the “Company”) is pleased to announce the third tranche of...
-
Los Angeles, California, March 30, 2022 (GLOBE NEWSWIRE) -- Crown Electrokinetics Corp. (NASDAQ: CRKN) ("Crown" or the "Company"), a leading smart glass technology company, will today report its...
-
RALEIGH, N.C., March 30, 2022 (GLOBE NEWSWIRE) -- Evergreen & Oak, the results-driven PR and marketing agency where strategy meets execution, launched today. Evergreen & Oak is founded by...
-
Boulder, Colorado, March 30, 2022 (GLOBE NEWSWIRE) -- TLT – Tour. Lite. Tech. This name has stood for speed, lightness, and efficiency for ski mountaineering since 1984. With the TLT X, we’re...
-
NORTH BILLERICA, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
-
Dublin, March 25, 2022 (GLOBE NEWSWIRE) -- The "Baby Products - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Baby Products Market to...
-
Company Announcement No 09/2022Peberlyk 46200 Aabenraa, DenmarkTel +45 70 10 78 79Fax +45 74 37 35 36Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk24 March 2022 Dear Sirs Annual General Meeting...
-
-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL -- -- 2022 submission...